

**BIOGRAPHICAL SKETCH**

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2.  
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

|   |                           |   |                   |
|---|---------------------------|---|-------------------|
| NAME<br>Jeffrey Dunn  |                           | POSITION TITLE<br>Professor of Clinical Neurology,<br>Chief, Division of Neuroimmunology<br>Neurology and Neurological Sciences |                   |
| eRA COMMONS USER NAME (credential, e.g., agency login)<br>Dunn.Jeffrey  |                           |   |                   |
| EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.) |                           |   |                   |
| INSTITUTION AND LOCATION  | DEGREE<br>(if applicable) | MM/YY   | FIELD OF STUDY    |
| Haverford College; Haverford, PA  | BA                        | 1983  | French Literature |
| Temple University School of Medicine; Phila., PA  | MD                        | 1989  | Medicine          |
| University of Washington; Seattle, WA   | Residency                 | 1993  | Neurology         |

Please refer to the application instructions in order to complete sections A, B, C, and D of the Biographical Sketch.

**A. Personal Statement**

I specialize in the diagnosis, treatment, and research of Multiple Sclerosis, Neuromyelitis Optica, Transverse Myelitis, and immunologically mediated diseases of the human nervous system. The Stanford MS Center is recognized as a Comprehensive Center of Care by the National Multiple Sclerosis Society, and is an active Member Center of the National Consortium of MS Centers. Together with the Neuroimmunology Clinic at the Stanford Neuroscience Health Center in Palo Alto, California, we have a clientele of > 6000 patients with multi-faceted diversity and an international referral base. See <https://www.youtube.com/watch?v=hBtpDlclr8c> Our research efforts include epidemiologic investigations and Phase II and III clinical trials, emphasizing translational research and interdisciplinary collaborations in our approach. A primary focus is the discovery of biomarkers of disease status, immunopathogenesis, and personalized medicine. This notably includes Project BIG as seen in <https://www.projectbig.com/> I presently serve as the elected Chairman of the MS Section of the American Academy of Neurology, and on the National MS Advisory Board of the National MS Society.

**B. Positions and Honors**

## Academic Positions Held:

|              |   |
|--------------|---|
| 1992-1993    | Chief Resident in Neurology, University of Washington; Seattle, WA  |
| 1993-1996    | Clinical Instructor in Medicine (Neurology), University of Washington; Seattle, WA  |
| 1997-2007    | Assistant Professor of Clinical Neurology; University of Washington; Seattle, WA  |
| 2008-2012    | Associate Professor of Clinical Neurology, Stanford University; Stanford, CA  |
| 2013-present | Professor of Clinical Neurology, Stanford University; Stanford, CA  |
| 2008-present | Chief, Division of Clinical Neuroimmunology, Department of Neurology, Stanford University Neuroscience Health Center: Palo Alto, CA |
| 2008-2019    | Neurology Clerkship Director, Stanford University; Stanford, CA   |
| 2010-2017    | Fellowship Director, MS and Clinical Neuroimmunology, Stanford Neurology  |
| 2011-2014    | Chair, MS Education Workgroup, Multiple Sclerosis General Section American Academy of Neurology; St. Paul, MN                       |
| 2014-2016    | Vice Chair, Executive Committee, MS General Section   |

Program Director/Principal Investigator (Last, First, Middle): Dunn, Jeffrey, Edward

American Academy of Neurology; peer elected 2010, peer re-elected 2012  
2018-2020 Chair, Multiple Sclerosis Section, American Academy of Neurology  
2018-present Member, National Medical Advisory Board; National Multiple Sclerosis Society  
2008-present Member, Association of University Professors of Neurology

#### Awards and Honors:

2008 Fellow, American Academy of Neurology  
2008-2017 Neurology Clerkship Student Teaching Award; Stanford University (each year)  
2008-2009 Lysia Forno Award for Outstanding Departmental Teaching; Stanford University  
Department of Neurology; Stanford, CA  
2009-2010 Excellence in Teaching Award; Stanford University School of Medicine  
2011 Arthur L. Bloomfield Award for Excellence in teaching Clinical Medicine;  
Stanford University School of Medicine; Stanford, CA  
2011 Successful Recruitment Award, AUPN; Minneapolis, MN  
2012 Successful Recruitment Award, AUPN; Minneapolis, MN  
2013 Henry J. Kaiser Family Foundation Award for Excellence in Clinical Instruction,  
Stanford University School of Medicine; Palo Alto, CA  
1998-2007 "America's Top Physicians," Consumers' Research Council of America; each year  
2010-2017 "Top Doctors," Castle Connolly Medical Ltd; each year inclusive  
2017 Arthur L. Bloomfield Award for Excellence in teaching Clinical Medicine;  
Stanford University School of Medicine; Stanford, CA  
2019 Healthcare Partner of the Year, National Multiple Sclerosis Society; Nor-Cal  
2019 A.B.Baker Teacher Recognition Award, American Academy of Neurology

#### C. Peer Reviewed Publications

1. The North American Registry for Care and Research in Multiple Sclerosis. Rammohan, K.W., Li, D., Halper, J., Murphy, S., Patton, L., China, A., Cohan, S., Cross, A.H., **Dunn, J.** et al. SAGE Publications LTD. 2019: 79-80
2. Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management. Open Forum Infectious Diseases. Epstein, D., **Dunn, J.**, Deresinski, S. 2018; 5 (8): ofy174. PubMedID 30094293
3. Ocrelizumab versus interferon beta in Relapsing Multiple Sclerosis. Hauser S. et al, **OPERA II Clinical Investigators**. *New England Journal of Medicine* 19 Jan 2017; 376: 22-234
4. Alemtuzumab improves pre-existing disability in active relapsing-remitting MS patients. Giovannoni G., et al, **CARE-MS II Investigators**. *Neurology* 2016; 87: 1985-1992
5. Interferon beta treatment requires B-cells for efficacy in neuro-autoimmunity. Schubert R., Hu Y., Kumar G., Szeto S., Abraham P., Winderl J., Guthridge JM, Pardo G., **Dunn J.**, Steinman L., Axtell R.C. *Journal of Immunology*, 2015; 194 (5): 2110-2116
6. Disease Modifying Therapies for non-relapsing Multiple Sclerosis: Absence of evidence does not constitute evidence of absence. **Dunn, J.** *Neurol Clin Pract*. December 2013; 3 (6): 515-518
7. Mobility Concerns in Multiple Sclerosis- Studies and Surveys on US patient populations of relevance to nurses. Lee, J., **Dunn J.** *US Neurology*; 2013; 9(1): 17-23
8. Analysis of B cell subsets in Multiple Sclerosis Patients on Immunomodulatory Therapy reveals Modulation of CD19+CD24hiCD38hi Cells with Implications for the Diagnosis and Monitoring of MS. Schubert, R., Goodyear, A., Abraham, P., Dunn, C., Steinman, L., **Dunn, J.**, Axtell, R. Lippincott Williams & Wilkins. 2013. Web of Science 000332068602192
9. Lublin, F. et al. and **CombiRx Investigators**. Randomized study combining interferon and glatiramer acetate in Multiple Sclerosis. *Ann Neurol* 2013 Mar; 73 (3): 327-340
10. The CombiRx Trial of Combined Therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and Baseline Characteristics. Lindsey, J. et. al. and **CombiRx Investigators**; *Mult Scler Relat Disord*: 2012 April 1; 1 (2): 81-86

11. Alemtuzumab for patients with relapsing Multiple Sclerosis after disease-modifying therapy: a randomized controlled Phase 3 trial. Coles AJ, et al. **CARE MS II Investigators**. *Lancet* 2012; 380: 1829-1839
12. Herges K, deJong BA, Kolkowitz I, Dunn C, Mandelbaum G, Ro RM, Maini A, Han, MH, Killestein J, Polman C, Goodyear A, **Dunn J**, Steinman L, Axtell RC; Protective effect of elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. *Multiple Sclerosis* 2012; 18 (4): 398-408
13. **Dunn J.**, Blight D. Dalfampridine: A Brief Review of Its Mechanism of Action and Efficacy as a Treatment to Improve Walking in Patients With Multiple Sclerosis; *Curr Med Res Opin.* 2011 Jul;27(7):1415-23
14. **Dunn J.** The impact of mobility impairment on the burden of caregiving in individuals with Multiple Sclerosis. *Expert Rev Pharmacoecon Outcomes Res*: 2010 Aug; 10 (4) 433-440
15. Pershing S., **Dunn J.**, Khan A., Liao JY (2009). CMV Optic Neuritis with extensive tracking along the visual pathway. *J Neuro-Ophthalmology*, 29 (3):223-226.
16. Fox EJ and the **TERMS Study Investigators** (2008). Tovaxin for early relapsing Multiple Sclerosis phase 2b Placebo controlled trial of autologous T cell vaccination in patients with CIS or MS. *Multiple Sclerosis*, (14);S5-S27.
17. Arnold D., Campagnolo D., Panitch H., Bar-Or A., **Dunn J.**, Freedman M., Gazda S.K., Vollmer T. (2008). Glatiramer Acetate after Mitoxantrone Induction Improves MRI Markers of lesion volume and permanent tissue injury in MS. *J Neurol*, 255, 1473-1478.
18. Vollmer T., Panitch H., Bar-Or A., **Dunn J.**, Freedman M.S., Gazda S.K., Campagnolo D., Deutsch F., Arnold D. (2008). Glatiramer Acetate after induction therapy with mitoxantrone in relapsing Multiple Sclerosis. *Multiple Sclerosis*, 14, 663-670.
19. Cohen J.A. and the **9006 Study Group** (2007). A randomized, double blind, dose comparison study of glatiramer acetate in relapsing remitting Multiple Sclerosis. *Neurology*, 68(12),939-944.
20. Later publications not listed to maintain 4 page biosketch: see <https://profiles.stanford.edu/jeffrey-dunn>

## Research Support

1. Project BIG Fund:The Brain, Immune, Gut Research Initiative in Multiple Sclerosis; 09/17-present
2. Consortium of Multiple Sclerosis Centers (CMSC): NARCRMS Toward the Development of a national longitudinal database in Multiple Sclerosis: 8/2018-7/2022
3. AMG Multiple Sclerosis Research Fund; 06/17-present
4. Genentech; Principal Investigator,  
"A Randomized Double Blind Double Dummy Parallel Group Study to Evaluate the Efficacy of Ocrelizumab in Comparison to Interferon beta in Patients with relapsing Multiple Sclerosis; 2012-present
5. Actelion; Principal Investigator  
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Three Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered for Twenty-four Weeks in Patients with Relapsing-remitting Multiple Sclerosis; 2010-present
6. Genzyme; Principal Investigator  
A Phase III randomized rater and dose blinded study comparing two annual cycles of intravenous low and high dose alemtuzumab to three times weekly subcutaneous interferon beta-1a in patients with relapsing remitting Multiple Sclerosis who have relapsed on therapy. 7/09-2016
7. National Multiple Sclerosis Society; Site Principal Investigator (E. Mowry PI)  
"A randomized controlled trial of vitamin D in multiple sclerosis." VIDAMS. 2012-2017